Lucitanib |
S-80881; AL-3810; CO-3810; E-3810; S-80881-2 |
Phase 3 Clinical |
Advenchen Laboratories Nanjing Ltd |
Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
Bemarituzumab |
FPA-144 |
Phase 3 Clinical |
Five Prime Therapeutics Inc |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Digestive System Neoplasms; Carcinoma, Squamous Cell; Adenocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Rogaratinib |
BAY-1163877 |
Phase 3 Clinical |
Bayer AG |
Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
Fexagratinib |
AZD4547; AZD-4547; ABSK-091; ABSK091 |
Phase 3 Clinical |
Astrazeneca Plc |
Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Glioma; Urinary Bladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms |
Details
|
Infigratinib |
BGJ-398; NVP-BGJ398 |
Phase 3 Clinical |
Novartis Pharma Ag |
Papillomavirus Infections; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Biliary Tract Neoplasms; Neoplasms; Achondroplasia; Nasopharyngeal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours |
Details
|
Efruxifermin |
AKR-001; AMG-876; EFX; Fc-FGF21(RGE) |
Phase 3 Clinical |
Amgen Inc |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus |
Details
|
SC-0011 |
SC-0011 |
Phase 3 Clinical |
Shijiazhuang Zhikang Hongren New Drug Development Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Zoligratinib |
CH-5183284; FF-284; Debio-1347 |
Phase 2 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
AUR-109 |
ODM-203; AUR-109 |
Phase 2 Clinical |
Orion Corp |
Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms |
Details
|
Derazantinib |
ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 |
Phase 2 Clinical |
Arqule Inc |
Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular |
Details
|
HH185 |
3D-185; 3-D185; HH-185; 3D185 |
Phase 2 Clinical |
ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc |
Solid tumours; Cholangiocarcinoma |
Details
|
3HP-2827 |
3HP-2827; 3HP2827 |
Phase 2 Clinical |
3H (Suzhou) Pharmaceuticals Co Ltd |
Solid tumours; Neoplasms |
Details
|
HMPL-453 |
HMPL-453 |
Phase 2 Clinical |
Hutchison Medipharma Ltd |
Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma |
Details
|
Lirafugratinib |
RLY-4008 |
Phase 2 Clinical |
Relay Therapeutics Inc |
Cholangiocarcinoma; Translocation, Genetic |
Details
|
Tasurgratinib |
E-7090 |
Phase 2 Clinical |
Eisai Co Ltd |
Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency |
Details
|
Sprifermin |
rhFGF-18; trFGF-18; FGF-18; zFGF-5; Zfgf5; AS-902330 |
Phase 2 Clinical |
Zymogenetics Inc |
Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee |
Details
|
Gunagratinib |
ICP-192 |
Phase 2 Clinical |
Beijing Tiancheng Pharmaceutical Technology Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms |
Details
|
BPI-17509 |
BPI-17509 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
TYRA-200 |
TYRA200; TYRA-200 |
Phase 1 Clinical |
Tyra Biosciences Inc |
Biliary Tract Neoplasms; Solid tumours; Cholangiocarcinoma; Bile Duct Neoplasms |
Details
|
Resigratinib |
KIN-3248; KIN-003 |
Phase 1 Clinical |
Kinnate Biopharma Inc |
Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma |
Details
|
Alofanib |
RPT-835 |
Phase 1 Clinical |
Russian Pharmaceutical Technologies Llc |
Stomach Neoplasms |
Details
|
TT-00434 |
TT-00434 |
Phase 1 Clinical |
TransThera Sciences (Nanjing) Inc |
Solid tumours; Urinary Bladder Neoplasms |
Details
|
ABSK-121 |
ABSK121-NX; ABSK121 |
Phase 1 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours |
Details
|
ABSK-061 |
ABSK061 |
Phase 1 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours |
Details
|
LY-2874455 |
LY-2874455 |
Phase 1 Clinical |
Eli Lilly And Company |
Neoplasms; Leukemia, Myeloid, Acute |
Details
|
CPL-304110 |
CPL-304110; CPL-304-110 |
Phase 1 Clinical |
Celon Pharma Sa |
Stomach Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
Lucitanib |
S-80881; AL-3810; CO-3810; E-3810; S-80881-2 |
Phase 3 Clinical |
Advenchen Laboratories Nanjing Ltd |
Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
Bemarituzumab |
FPA-144 |
Phase 3 Clinical |
Five Prime Therapeutics Inc |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Digestive System Neoplasms; Carcinoma, Squamous Cell; Adenocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Rogaratinib |
BAY-1163877 |
Phase 3 Clinical |
Bayer AG |
Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
Fexagratinib |
AZD4547; AZD-4547; ABSK-091; ABSK091 |
Phase 3 Clinical |
Astrazeneca Plc |
Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Glioma; Urinary Bladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms |
Details
|
Infigratinib |
BGJ-398; NVP-BGJ398 |
Phase 3 Clinical |
Novartis Pharma Ag |
Papillomavirus Infections; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Biliary Tract Neoplasms; Neoplasms; Achondroplasia; Nasopharyngeal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours |
Details
|
Efruxifermin |
AKR-001; AMG-876; EFX; Fc-FGF21(RGE) |
Phase 3 Clinical |
Amgen Inc |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus |
Details
|
SC-0011 |
SC-0011 |
Phase 3 Clinical |
Shijiazhuang Zhikang Hongren New Drug Development Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Zoligratinib |
CH-5183284; FF-284; Debio-1347 |
Phase 2 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
AUR-109 |
ODM-203; AUR-109 |
Phase 2 Clinical |
Orion Corp |
Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms |
Details
|
Derazantinib |
ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 |
Phase 2 Clinical |
Arqule Inc |
Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular |
Details
|
HH185 |
3D-185; 3-D185; HH-185; 3D185 |
Phase 2 Clinical |
ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc |
Solid tumours; Cholangiocarcinoma |
Details
|
3HP-2827 |
3HP-2827; 3HP2827 |
Phase 2 Clinical |
3H (Suzhou) Pharmaceuticals Co Ltd |
Solid tumours; Neoplasms |
Details
|
HMPL-453 |
HMPL-453 |
Phase 2 Clinical |
Hutchison Medipharma Ltd |
Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma |
Details
|
Lirafugratinib |
RLY-4008 |
Phase 2 Clinical |
Relay Therapeutics Inc |
Cholangiocarcinoma; Translocation, Genetic |
Details
|
Tasurgratinib |
E-7090 |
Phase 2 Clinical |
Eisai Co Ltd |
Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency |
Details
|
Sprifermin |
rhFGF-18; trFGF-18; FGF-18; zFGF-5; Zfgf5; AS-902330 |
Phase 2 Clinical |
Zymogenetics Inc |
Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee |
Details
|
Gunagratinib |
ICP-192 |
Phase 2 Clinical |
Beijing Tiancheng Pharmaceutical Technology Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms |
Details
|
BPI-17509 |
BPI-17509 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
TYRA-200 |
TYRA200; TYRA-200 |
Phase 1 Clinical |
Tyra Biosciences Inc |
Biliary Tract Neoplasms; Solid tumours; Cholangiocarcinoma; Bile Duct Neoplasms |
Details
|
Resigratinib |
KIN-3248; KIN-003 |
Phase 1 Clinical |
Kinnate Biopharma Inc |
Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma |
Details
|
Alofanib |
RPT-835 |
Phase 1 Clinical |
Russian Pharmaceutical Technologies Llc |
Stomach Neoplasms |
Details
|
TT-00434 |
TT-00434 |
Phase 1 Clinical |
TransThera Sciences (Nanjing) Inc |
Solid tumours; Urinary Bladder Neoplasms |
Details
|
ABSK-121 |
ABSK121-NX; ABSK121 |
Phase 1 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours |
Details
|
ABSK-061 |
ABSK061 |
Phase 1 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours |
Details
|
LY-2874455 |
LY-2874455 |
Phase 1 Clinical |
Eli Lilly And Company |
Neoplasms; Leukemia, Myeloid, Acute |
Details
|
CPL-304110 |
CPL-304110; CPL-304-110 |
Phase 1 Clinical |
Celon Pharma Sa |
Stomach Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|